Design and analysis of metabolomics studies in epidemiologic research: A primer on-omic technologies

American Journal of Epidemiology

Volumn 180, Issue 2, 2014, Pages 129-139

  Tzoulaki, Ioanna ^a   Ebbels, Timothy M D ^a   Valdes, Ana ^a   Elliott, Paul ^a   Ioannidis, John P A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

metabolic profiling; metabolome wide association studies; metabolomics

Indexed keywords

BIOACCUMULATION; DATA PROCESSING; DESIGN; EPIDEMIOLOGY; METABOLISM; MOLECULAR ANALYSIS; RESEARCH WORK;

CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; EPIDEMIOLOGY; FEMALE; HUMAN; MALE; MEASUREMENT ERROR; METABOLITE; METABOLOMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; REVIEW; STATISTICAL ANALYSIS;

METABOLIC PROFILING; METABOLOME-WIDE ASSOCIATION STUDIES; METABOLOMICS;

ANALYSIS OF VARIANCE; EPIDEMIOLOGIC METHODS; HUMANS; METABOLOMICS;

EID: 84903983520     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwu143     Document Type: Review

References (64)

1. Bictash M, Ebbels TM, Chan Q, et al. Opening up the "Black Box": metabolic phenotyping and metabolome-wide association studies in epidemiology. J Clin Epidemiol. 2010; 63(9):970-979.
2. Holmes E,Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell. 2008;134(5):714-717.
3. Nicholson JK, Lindon JC. Systems biology: metabonomics. Nature. 2008;455(7216):1054-1056.
4. Nicholson JK, Holmes E, Kinross JM, et al. Metabolic phenotyping in clinical and surgical environments. Nature. 2012;491(7424):384-392.
5. Wishart DS, Tzur D, Knox C, et al. HMDB: the Human Metabolome Database. Nucleic Acids Res. 2007; 35(Database issue):D521-D526.
6. Shah SH, Kraus WE, Newgard CB. Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. Circulation. 2012;126(9):1110-1120.
7. Verma M, Khoury MJ, Ioannidis JP. Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling. Cancer Epidemiol Biomarkers Prev. 2013;22(2):189-200.
8. Lindon JC, Nicholson JK. Analytical technologies for metabonomics and metabolomics, and multi-omic information recovery. Trends Analyt Chem. 2008;27(3):194-204.
9. Gika HG, Theodoridis GA, Wilson ID. Liquid chromatography and ultra-performance liquid chromatography-mass spectrometry fingerprinting of human urine: sample stability under different handling and storage conditions for metabonomics studies. J Chromatogr A. 2008;1189(1-2):314-322.
10. Gika HG, Theodoridis GA, Wingate JE, et al. Within-day reproducibility of an HPLC-MS-based method for metabonomic analysis: application to human urine. J Proteome Res. 2007;6(8):3291-3303.
11. Weiss RH, Kim K. Metabolomics in the study of kidney diseases. Nat Rev Nephrol. 2011;8(1):22-33.
12. Teahan O, Gamble S, Holmes E, et al. Impact of analytical bias in metabonomic studies of human blood serum and plasma. Anal Chem. 2006;78(13):4307-4318.
13. Sugimoto M, Wong DT, Hirayama A, et al. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics. 2010;6(1):78-95.
14. Wei J, Xie G, Zhou Z, et al. Salivary metabolite signatures of oral cancer and leukoplakia. Int J Cancer. 2011;129(9): 2207-2217.
15. Suhre K, Meisinger C, Döring A, et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS One. 2010;5(11):e13953.
16. Chadeau-Hyam M, Campanella G, Jombart T, et al. Deciphering the complex: methodological overview of statistical models to derive OMICS-based biomarkers. Environ Mol Mutagen. 2013;54(7):542-557.
17. De Livera AM, Dias DA, De Souza D, et al. Normalizing and integrating metabolomics data. Anal Chem. 2012;84(24): 10768-10776.
18. De Livera AM, Olshansky M, Speed TP. Statistical analysis of metabolomics data. Methods Mol Biol. 2013;1055: 291-307.
19. Issaq HJ, Van QN,Waybright TJ, et al. Analytical and statistical approaches to metabolomics research. J Sep Sci. 2009;32(13): 2183-2199.
20. Korman A, Oh A, Raskind A, et al. Statistical methods in metabolomics. Methods Mol Biol. 2012;856:381-413.
21. Want E, Masson P. Processing and analysis of GC/LC-MS-based metabolomics data. In: Metz TO, ed. Metabolic Profiling. New York, NY: Humana Press; 2011:277-298.
22. Ebbels TM, Lindon JC, Coen M. Processing and modeling of nuclear magnetic resonance (NMR) metabolic profiles. Methods Mol Biol. 2011;708:365-388.
23. Liebeke M, Hao J, Ebbels TMD, et al. Combining spectral ordering with peak fitting for one-dimensional NMR quantitative metabolomics. Anal Chem. 2013;85(9): 4605-4612.
24. Blaise BJ, Navratil V, Domange C, et al. Two-dimensional statistical recoupling for the identification of perturbed metabolic networks from NMR spectroscopy. J Proteome Res. 2010;9(9):4513-4520.
25. Dunn WB, Broadhurst D, Begley P, et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc. 2011;6(7):1060-1083.
26. Viant MR. Revealing the metabolome of animal tissues using 1H nuclear magnetic resonance spectroscopy. Methods Mol Biol. 2007;358:229-246.
27. Smith CA,Want EJ, O'Maille G, et al. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem. 2006; 78(3):779-787.
28. Pluskal T, Castillo S, Villar-Briones A, et al. MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics. 2010;11:395.
29. Scheltema RA, Jankevics A, Jansen RC, et al. PeakML/mzMatch: a file format, java library, R library, and tool-chain for mass spectrometry data analysis. Anal Chem. 2011;83(7): 2786-2793.
30. Hotelling H. Analysis of a complex of statistical variables into principal components. J Educ Psychol. 1993;24(6): 417-441.
31. Wold S, Ruhe A, Wold H, et al. The collinearity problem in linear regression. The partial least squares (PLS) Approach to generalized inverses. SIAM J Sci Stat Comput. 1984;5(3): 735-743.
32. Trygg J, Wold S. Orthogonal projections to latent structures (O-PLS). J Chemometr. 2002;16(3):119-128.
33. Trygg J, Wold S. O2-PLS, a two-block (X-Y) latent variable regression (LVR) method with an integral OSC filter. J Chemometr. 2003;17(1):53-64.
34. Fonville JM, Richards SE, Barton RH, et al. The evolution of partial least squares models and related chemometric approaches in metabonomics and metabolic phenotyping. J Chemometr. 2010;24(11-12):636-649.
35. Bottolo L, Chadeau-Hyam M, Hastie DI, et al. ESS++: a C++ objected-oriented algorithm for Bayesian stochastic search model exploration. Bioinformatics. 2011;27(4):587-588.
36. The R project. The Comprehensive R Archive Network. http://cran.r- project.org/. Accessed May 1, 2014.
37. Umetrics. SIMCA: the standard in multivariate data analysis. http://www.umetrics.com/products/simca. Accessed May 1, 2014.
38. Castaldi PJ, Dahabreh IJ, Ioannidis JP. An empirical assessment of validation practices for molecular classifiers. Brief Bioinform. 2011;12(3):189-202.
39. Ioannidis JP, Khoury MJ. Improving validation practices in "omics" research. Science. 2011;334(6060):1230-1232.
40. Ioannidis JP. Expectations, validity, and reality in omics. J Clin Epidemiol. 2010;63(9):945-949.
41. Chadeau-Hyam M, Ebbels TM, Brown IJ, et al. Metabolic profiling and the metabolome-wide association study: significance level for biomarker identification. J Proteome Res. 2010;9(9):4620-4627.
42. Evangelou E, Ioannidis JP. Meta-analysis methods for genome-wide association studies and beyond. Nat Rev Genet. 2013;14(6):379-389.
43. Krumsiek J, Suhre K, Evans AM, et al. Mining the unknown: a systems approach to metabolite identification combining genetic and metabolic information. PLoS Genet. 2012;8(10): e1003005.
44. Fiehn O, Garvey WT, Newman JW, et al. Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women. PLoS One. 2010;5(12):e15234.
45. Cloarec O, Dumas ME, Craig A, et al. Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Anal Chem. 2005;77(5):1282-1289.
46. Xia J, Wishart DS. MSEA: a web-based tool to identify biologically meaningful patterns in quantitative metabolomic data. Nucleic Acids Res. 2010;38(web server issue):W71-W77.
47. Gao J, Tarcea VG, Karnovsky A, et al. Metscape: a Cytoscape plug-in for visualizing and interpreting metabolomic data in the context of human metabolic networks. Bioinformatics. 2010; 26(7):971-973.
48. Suhre K, Schmitt-Kopplin P. MassTRIX: mass translator into pathways. Nucleic Acids Res. 2008;36(web server issue): W481-W484.
49. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17(4):448-453.
50. Wang-Sattler R, Yu Z, Herder C, et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol. 2012;8: 615.
51. Cheng S, Rhee EP, Larson MG, et al. Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation. 2012;125(18):2222-2231.
52. Ferrannini E, Natali A, Camastra S, et al. Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. Diabetes. 2013;62(5): 1730-1737.
53. Floegel A, Stefan N, Yu Z, et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes. 2013;62(2): 639-648.
54. Bain JR, Muehlbauer MJ. Metabolomics reveals unexpected responses to oral glucose. Diabetes. 2013;62(8):2651-2653.
55. Würtz P, Soininen P, Kangas AJ, et al. Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care. 2013;36(3):648-655.
56. Ioannidis JP, Tzoulaki I. What makes a good predictor? The evidence applied to coronary artery calcium score. JAMA. 2010;303(16):1646-1647.
57. Siontis GC, Tzoulaki I, Ioannidis JP. Predicting death: an empirical evaluation of predictive tools for mortality. Arch Intern Med. 2011;171(19):1721-1726.
58. Siontis GC, Tzoulaki I, Siontis KC, et al. Comparisons of established risk prediction models for cardiovascular disease: systematic review. BMJ. 2012;344:e3318.
59. Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA. 2009;302(21):2345- 2352.
60. Tzoulaki I, Liberopoulos G, Ioannidis JP. Use of reclassification for assessment of improved prediction: an empirical evaluation. Int J Epidemiol. 2011;40(4):1094-1105.
61. Holmes E, Loo RL, Stamler J, et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature. 2008;453(7193):396- 400.
62. Menni C, Fauman E, Erte I, et al. Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. Diabetes. 2013;62(12):4270-4276.
63. Khoury MJ, Lam TK, Ioannidis JP, et al. Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev. 2013;22(4): 508-516.
64. Haug K, Salek RM, Conesa P, et al. MetaboLights-an open-access general-purpose repository for metabolomics studies and associated meta-data. Nucleic Acids Res. 2013; 41(D1):D781-D7D6.